CIPO Patents = 1

EPO Patents = 1

Forward Citations = 5

Loading Chart...

2 inventors (with patents filed for the assignee):

David M Tsai (4 out of 24 patents)

David Men Hwei Tsai (1 out of 1 patent)

Men Hwei Tsai (3 patents)

5 patents: Sort by Forward Citations

1. 7528108 - Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments (2009-05-05),

2. 7445784 - Polypeptide for the treatment of cancer and a method for preparation thereof (2008-11-04),

3. 7238662 - Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof (2007-07-03),

4. 6352729 - Plant extract that inhibits the release of tumor necrosis factor alpha (TNF-alpha) (2002-03-05),

5. 6312737 - Method of inducing apoptosis in cancer cells using an extract of Melothria indica Lou (2001-11-06),

Ambryx Biotechnology, Inc. is a leading biotech company focused on developing innovative therapeutics for a variety of diseases. With a strong emphasis on research and development, Ambryx is committed to improving patient outcomes and advancing medical science. Their team of experts includes renowned scientists and industry veterans dedicated to making a positive impact in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

5 Patents

#23 in Riverside, CA

#11,741 in California

#50,255 in US

Riverside, CA, United States of America

Ambryx Biotechnology, Inc.

Forward Citations = 5

2 inventors:

David M Tsai (4 out of 24 patents)

David Men Hwei Tsai (1 out of 1 patent)

Men Hwei Tsai (3 patents)

Please report any incorrect information to support@idiyas.com

1 patent (CIPO):

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com